Skip to main content
Scholars@Duke
Menu
About
Schools / Institutes
Browse
Thomas Joseph Povsic
Adjunct Professor of Medicine
Medicine, Cardiology
povsi001@mc.duke.edu
Duke Box 103208, Durham, NC 27710
DUMC Box 103208, Durham, NC 27710
Research
More About This Person
glance {hide_children: true, active: false, enabled: true}
At a Glance
credentials {hide_children: true, active: false, enabled: true}
Credentials
Education
Training & Certifications
academic-experience {hide_children: true, active: false, enabled: true}
Academic Experience
Current Appointments & Affiliations
Previous Appointments & Affiliations
expertise {hide_children: true, active: false, enabled: false}
Expertise
research {hide_children: false, active: true, enabled: true}
Research
Selected Grants
publications {hide_children: true, active: false, enabled: true}
Publications
Selected Publications
artistic-works {hide_children: true, active: false, enabled: false}
Artistic Works / Events
teaching {hide_children: true, active: false, enabled: false}
Teaching
advising-mentoring {hide_children: true, active: false, enabled: false}
Advising & Mentoring
recognition {hide_children: true, active: false, enabled: false}
Recognition
professional-activities {hide_children: true, active: false, enabled: false}
Professional Activities
Manage Profile
Embed Profile Data
Manage Profile
Embed Profile Data
Selected Grants
A Phase 1/2 Trial of Direct Administration of AdVEGF-All6A+, a Replication Deficient Adenovirus Vector Expressing a cDNA/Genomic Hybrid of Human Vascular Endothelial Growth Factor, to the Ischemic Myocardium of Subjects with Angina Pectoris Secondary
Clinical Trial
Principal Investigator ·
Awarded by XyloCor Therapeutics ·
2019 - 2024
Direct Administration of AdVEGF-All6A+ LOI
Research
Principal Investigator ·
Awarded by XyloCor Therapeutics ·
2020 - 2023
DREAM-HF
Clinical Trial
Principal Investigator ·
Awarded by Mesoblast International Sarl ·
2014 - 2021
Randomized, Double-Blind, Placebo-Controlled Phase I/II Study of the Safety and Efficacy of Intracoronary Delivery of Allogeneic Cardiosphere-Derived Cells in Patients With an Anterior Myocardial Infarction and Ischemic Left Ventricular Dysfunction
Clinical Trial
Principal Investigator ·
Awarded by Capricor Therapeutics, Inc. ·
2014 - 2021
A Randomized, Double-Blind, Placebo-Controlled, Safety and Tolerability Study of Escalating Single Doses of ITI-214 in Patients with Systolic Heart Failure
Clinical Trial
Principal Investigator ·
Awarded by Intra-Cellular Therapies, Inc. ·
2017 - 2020
RECARDIO - REC-DUT-002
Clinical Trial
Principal Investigator ·
Awarded by Recardio, Inc ·
2018 - 2020
CD34+ Biologics
Research
Principal Investigator ·
Awarded by Caladrius Biosciences, Inc. ·
2018 - 2019
A Biomarker Study of the APEX-AMI and SOLSTICE Trial Populations
Research
Principal Investigator ·
Awarded by GlaxoSmithKline ·
2016 - 2018
Aptamer-based affinity capture of circulating CAD EPCs
Research
Investigator ·
Awarded by National Institutes of Health ·
2013 - 2016
Adipose-derived regenerative cells in the Treatment of patients with chronic ischemic HEart disease Not Amenable to surgical or interventional revascularization
Clinical Trial
Principal Investigator ·
Awarded by Cytori Therapeutics, Inc. ·
2014 - 2016
EPC Adhesion to Teflon-AF and ePTFE Vascular Grafts
Research
Investigator ·
Awarded by National Institutes of Health ·
1990 - 2013
REVEAL (Reduction of Infarct Expansion & Ventricular remodeling with Epo Admin after Large MI)
Clinical Trial
Co Investigator ·
Awarded by National Institutes of Health ·
2005 - 2011
Assessing Circulating Progenitor Cells in Heart Disease
Research
Principal Investigator ·
Awarded by National Institutes of Health ·
2006 - 2008
Blood pressure, endothelial cell dysfunction and outcomes in kidney disease
Clinical Trial
Collaborator ·
Awarded by National Institutes of Health ·
2008 - 2008
